Dr. Ricardo Correa

Dr. Ricardo Correa |Clyto Access

Brown University, USA


Expertise: Neuroendocrinology, Adrenal tumor and New Genetic Mutations


Ricardo Correa, M.D., Es. D., F.A.C.P., C.M.Q. is an Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University in the Department of Endocrinology, Diabetes and Metabolism.  He is the chair of the young physician subcommittee of the American Association of Clinical Endocrinologist (YPS-AACE). Also, he is editor of Dynamed and outreach unit director of Endotext.org and Thyroid manager. He completed his Medical School and Education Master at University of Panama. He completed a research fellowship in Epidemiology and Tropical disease at ICGES in Panama City and his internal medicine residency at Jackson Memorial hospital-University of Miami (UM) program. In 2012, he was honored with the AOAand GoldDOC Award from the UM. Then he pursued his clinical and research fellowship in endocrinology with special focus in neuroendocrinology and adrenalsat National Institute of Health.He was trained in Evidence-based Medicine at McMaster University in Canada and in the Editorial process and OJS by LATINDEX. He is co-director of the Panamanian Cochrane Center and EBM advocate.Dr. Correa has been involved in organized medicine since medical school. He has been scientific committee chair and vice speaker for the AMA-RFS, chair of the CoA for the ACP FC, Board of Trustee of the Maryland Medical Society, National Secretary of the CoA for the NHMA, Regional Vice President of the CIR, Medical Education Officer of JDN-WMA. He has been involving with local, regional and national organization in the area of medical education, leadership and physician wellbeing including the AMA joy in medicine organization, ACGME at different level including the duty hour task force, NBME as part of the board, NBPAS and other organization. At AACE and ACE and Endocrine Society,  Dr. Correa has occupied a different position from been the fellow-in-training board of director member to member and advisor of multiple committees throughout the years.Dr. Correa has been involved in multiple academic, scientific and educational activities including article Consultant, Interpretation of the Medical Literature Project, NBME, International Committee member of the Committee on Publications ethics (COPE), World Association of Medical Editors, Deputy Editor of International Archives of Medicine, Editorial board and peer reviewer of multiple journals including Annals of Public Health, PAHO Journal, SGIM journal, International Journal of Endocrinology, International Journal of Diabetes, International Journal of Clinical Cases and Images, International journal of case reports, etc. Also, he is a consultant for Latin American science center including Bolivia and Panama national science department.He is board certified in Medical Quality. He is the author of the book title “Case report: basics and publication”. 



Title: Severe hypertriglyceridemia (HTG) and Acute Pancreatitis (AP): an evidence update of the literature


Severe HTG is related to AP; in contrast, with mild-moderate HTG that is related with CVD. Triglycerides (TG) may derive from de novo free fatty acid (FFA) synthesis in the liver or from the uptake of remnant chylomicrons, VLDL, or FFA from the plasma. Lipoprotein Lipase (LPL) hydrolyzed them into FFA for uptake by muscle and adipose tissue, whereas remnants of VLDL and chylomicrons are removed by the liver. The most common primary cause of HTG in adults is familial HTG, with a population prevalence ranging from 1-10% and age-dependent penetrance. The most common secondary condition associated with HTG is obesity.HTG is an uncommon but well documented cause of AP, accounting for 1–4% of cases. Pathogenesis of this problem still unclear. The chronic management of HTG is very well understood. In contrast, the acute management of AP due to HTG is not standardizes and there is poor evidence. We performed a literature review on this topic and will summarize all the different studies with the level of evidence for each of the management of AP due to severe HTG. We will try to clarify the controversy found in the different guidelines on the use of these therapies. We will give a special focus on apheresis as a feasible option.In the acute setting of AP, besides NPO and supportive treatment the use of insulin, heparin and apheresis are good option to decrease the TG as fast as you can to prevent the progression and complications of AP.


Related Conferences :

International Diabetes and Degenerative Diseases Conference